Form 4: Marimed CCO Crandall's Equity Grant & Promotion

Marimed Inc.'s Chief Commercial Officer, Ryan Crandall, received a significant RSU grant and vested existing units, reflecting his recent promotion.

Summary

• Ryan Crandall, Chief Commercial Officer of Marimed Inc. (MRMD), reported transactions involving company common stock and Restricted Stock Units (RSUs).
• On December 15, 2025, Crandall acquired 62,902 shares of common stock upon the vesting of previously granted RSUs, with a transaction price of $0.
• Concurrently, 18,462 shares were disposed of at a price of $0.1071 to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Crandall beneficially owned 867,515 shares of common stock.
• Additionally, Crandall was granted 1,000,000 new Restricted Stock Units (RSUs) on December 15, 2025, with a transaction price of $0.
• These new RSUs will vest in four equal installments on June 15, 2026, December 15, 2026, June 15, 2027, and December 15, 2027.
• The 1,000,000 RSU grant was issued in lieu of a cash salary increase, coinciding with Crandall's promotion to Chief Commercial Officer.

Sentiment

Score: 8

Explanation: The filing indicates a significant positive development for the executive, including a promotion and a substantial equity grant. This suggests confidence in the company's future and a commitment to retaining key talent, which is generally positive for the company's outlook.

Positives

• Ryan Crandall was promoted to Chief Commercial Officer, indicating career progression and increased responsibility within Marimed Inc.
• The grant of 1,000,000 new Restricted Stock Units (RSUs) demonstrates significant equity compensation and aligns executive incentives with shareholder value.
• The RSU grant was issued in lieu of a cash salary increase, potentially conserving company cash while still providing competitive compensation.

Negatives

• 18,462 shares of common stock were disposed of to cover tax withholding obligations, resulting in a reduction of direct share ownership.

Future Outlook

The newly granted 1,000,000 Restricted Stock Units (RSUs) will vest in four equal installments on June 15, 2026, December 15, 2026, June 15, 2027, and December 15, 2027, aligning the executive's long-term incentives with company performance.

Management Comments

• The RSUs granted on December 15, 2025, were issued in lieu of a cash salary increase in connection with the Reporting Person's promotion to Chief Commercial Officer.

Industry Context

This Form 4 filing reflects a standard practice of executive compensation within publicly traded companies, where equity grants like Restricted Stock Units (RSUs) are used to incentivize and retain key management personnel. The promotion of a Chief Commercial Officer and subsequent equity grant is a common strategic move to strengthen leadership and align interests with long-term company growth, particularly in competitive industries.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a significant component of executive compensation is a widely adopted practice across various industries, including the cannabis sector where Marimed operates. This method is favored for its ability to align executive interests with shareholder value over a multi-year vesting period.
• The grant of 1,000,000 RSUs to a newly promoted Chief Commercial Officer is a substantial equity award, comparable to grants seen in similar-sized companies for key executive roles, reflecting the importance of the position and the company's commitment to long-term incentives.
• The practice of issuing equity in lieu of a cash salary increase is also common, especially for growth-oriented companies, as it helps conserve cash flow while still providing competitive and motivating compensation packages.

Management Changes

Stakeholder Impact

• Shareholders: The grant of 1,000,000 RSUs could lead to future dilution as these units convert to common stock, but it also aligns the Chief Commercial Officer's interests with long-term shareholder value.
• Employees: The promotion of Ryan Crandall may signal internal growth opportunities and a stable leadership structure.
• Management: The promotion and significant equity compensation package for the Chief Commercial Officer indicate strong executive retention and motivation.

Next Steps

• The 1,000,000 new RSUs will vest in four equal installments on June 15, 2026, December 15, 2026, June 15, 2027, and December 15, 2027.

Key Dates

Keywords

Marimed, MRMD, Ryan Crandall, Form 4, RSU, Restricted Stock Units, Stock Grant, Executive Compensation, Chief Commercial Officer, Insider Transaction